Medicare Part D Use and Costs for Immune-Mediated Neurologic Therapies

This economic evaluation examines trends in claims and Medicare Part D payments for disease-modifying therapies for multiple sclerosis, neuromyelitis optica spectrum disorder, and other immune-mediated neurologic disorders.

READ MORE